SPONSOR
West German Study Group
Total Trials
2
Recruiting
2
Phases
Phase 3
NCT05792150
Recruiting
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
Female Breast Cancer
NCT06081244 Phase 3
Recruiting
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Triple Negative Breast Cancer